Skip to main
BIO

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is a leading developer and seller of products and solutions in the clinical diagnostics and life sciences markets. With a diverse geographical presence and a leadership position in dPCR technology, the company is well-positioned for long-term growth. Despite recent market challenges, the company's sales growth is expected to recover in 2027, driven by the resolution of idiosyncratic headwinds and management's efforts to improve margin profiles. Additionally, the potential monetization of Bio-Rad's significant ownership stake in Sartorius, which is set to increase in mid-2028, presents a compelling asset value. However, risks to the company's outlook include potential delays in end-market recovery, loss of market share in ddPCR, and challenges in M&A integration.

Bears say

Bio-Rad Laboratories is facing several challenges, including limited sustainability integration and a track record of heavy restructuring. In addition, the company's reliance on the clinical diagnostics market, which accounts for 60% of its sales, exposes it to potential risks. Furthermore, Bio-Rad's stake in Sartorius, which accounts for 33% ownership, may not provide enough value to offset these challenges. These factors, along with potential risks such as end market recovery delays and share losses in ddPCR, lead to our negative outlook on the company's stock.

Bio-Rad Laboratories (BIO) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Hold based on their latest research and market trends.

According to 3 analysts, Bio-Rad Laboratories (BIO) has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $350, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $350, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.